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Classification 
Benign epithelial lesions with no significant tendency 











- radial scar/complex sclerosing lesions 
Invasive breast carcinomas are divided into two 
major categories on the basis of their cytoarchitectural 
features: 
- Invasive ductal carcinoma: 
-- acinic cell carcinoma 
-- adenoid cystic carcinoma 
-- apocrine carcinoma 
-- cribriform carcinoma 
-- glycogen-rich/clear cell 
-- inflammatory carcinoma 
-- lipid-rich carcinoma 
-- medullary carcinoma 
-- metaplastic carcinoma 
-- micropapillary carcinoma 
-- mucinous carcinoma 
-- neuroendocrine carcinoma 
-- oncocytic carcinoma 
-- papillary carcinoma 
-- sebaceous carcinoma 
-- Secretory Breast Carcinoma 
-- tubular carcinoma 
- lobular carcinoma 
-- pleomorphic 
-- signet ring cell 
The recognized precursor lesions of invasive breast 
carcinoma are: 
- intraductal proliferative lesions: 
-- atypical ductal hyperplasia 
-- ductal carcinoma in situ 
-- florid 
-- usual 
- lobular neoplasia/atypical lobular. 
The terminology Invasive ductal/lobular carcinoma 
does not imply an origin form ducts and lobules, 
respectively, but the presence of cytoarchitectural and 
phenotypical features of ductal-type and lobular-type, 
respectively. 
Ductal adenocarcinoma is the most common. Lobular 
carcinoma is the second malignant breast tumour. 
Medullary carcinoma is rare. 
Hyperplasia is a proliferation without criteria of 
malignancy. 
Fibroadenomas are benign breast tumours. 
Clinics and pathology 
Etiology 
The etiology is multifactorial. It involves diet, genetic 
and reproductive factors, and related hormone 
imbalances. 
Epidemiology 
The annual incidence of breast cancer is about 43/100 
000 per year in France, and the mortality rate is about 
18/100 000 per year. Invasive breast cancer is the most
common carcinoma in women, accounting for 22% of 
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all female cancers. One million women worldwide are
diagnosed with breast cancer every year. 
The main factors of risk are: 
Gender: women's risk for the development of invasive 
breast carcinoma is approximately 400 times that of 
men. 
Age: breast cancer incidence increases rapidly with 
age. The mean age at diagnosis is around 60 yrs. 
Genetic factors: rare (3 to 5% of cancers and 1/500-800 
women) but highly predictive of the disease.  
The areas of higher risk are the affluent populations f 
North America, Europa and Australia, where 6% of 
women develop invasive breast carcinoma before age 
75. 
Pathology 
The most common histologic type of invasive breast 
carcinoma is designated as ductal, NOS (not otherwise 
specified). It comprises about 80% of all cases. It is a 
proliferation of epithelial cells from galactophoral 
ducts; it may be preceded and accompanied by an in 
situ component characterized by a proliferation of cells 
within the ducts without interuption of the basal 
membrane; when this membrane is altered, the 
carcinoma is invasive. It can be graded on the basis of 
the architecture (amount of tubule formations), nuclear 
atypia and mitotic activity. The score resulting from the 
sum of these criteria (NottinghamÕs score) has been 
show to be an important prognostic indicator. A 3-
grade system has been developed for in situ ductal 
carcinoma. Grade III in situ ductal carcinoma 
corresponds to the classic comedocarcinoma, whereas 
Grade I in situ ductal carcinoma merges with atypical 
ductal hyperplasia, to the point that some authors 
regard the two process as one and the same. Recently, a 
proposal has been made to embrace all of the various 
types of intraductal proliferative lesions under the erm 
ductal intraepithelial neoplasia (DIN) and to divide this 
into 3 grades, having increasingly higher risk for the 
development of  invasive carcinoma. 
Many morphologic variants of invasive ductal 
carcinoma exist, some of them extremely rare. They 
include: tubular, cribriform, medullary, mucinous, 
neuroendocrine, papillary, micropapillary, apocrine, 
metaplastic, lipid-rich, secretory, oncocytic, adenoid 
cystic, acinic cell, glycogen-rich (clear cell), sebaceous, 
and inflammatory carcinoma. The prognosis of these 
subtypes varies, some of them having a better and some 
a worse outcome than invasive ductal carcinoma, NOS. 
Invasive lobular carcinoma is the second major  
type (5-10%) of breast cancer. Like its ductal 
counterpart, it may be preceded or accompanied by an 
in situ component. It is histologically more 
homogeneous than ductal carcinoma, but some 
morphologic variation exist, such as pleomorphic and 
signet ring cell. 
 
Medullary carcinoma, already mentioned above as a 
rare subtype of invasive ductal carcinoma (1%) with a 
better prognosis, it has a very distinctive form: sharply 
circumscribed, accompanied by a heavy lymphoid 
infiltrate, of high nuclear grade, with a syncytial pattern 
of growth, and lacking in situ  or microglandular 
features. When one of these features is lacking, the 
tumor is referred to as Òatypical medullary carcinoma". 
A high frequency of medullary carcinoma has been 
reported in patients with BRCA1 germ line mutation. 
The different steps in the progression of breast cancer 
are not well individualized. 
Hyperplasia is a proliferation of ductal or lobular 
epithelial cells, without criteria of malignancy; in 
contrast, atypical hyperplasia has incomplete malign nt 
features and can be difficult to distinguish from in s tu 
carcinoma. 
Fibroadenomas are the most common form of benign 
breast tumors. 
These different forms of breast cancer may occur with
(hereditary or familial forms) or without (sporadic 
forms) a familial background. 
Prognosis 
There are over 100 factors that have been identified as 
having prognostic significance in breast carcinoma, but 
only a minority of them will retain this property when 
subjected to a multivariate analysis. The most 
important prognostic factors are: presence and number 
of positive lymph nodes; tumor size; microscopic 
grade; and presence of lymphovascular invasion. Other 
parameters examined pathologically - such as hormone 
receptors and ERBB2/Neu - have more of a predictive 
than a prognostic value, in the sense of anticipating a 
certain type of response to specific forms of therapy. 
Upon diagnosis, the different presentations are 
classified upon morphological study, and the gravity 
and prognosis of the disease is estimated with several 
parameters that are: 
tumor size, 
tumor grade: it is calculated from assessment of tubular 
differentiation, number of mitoses, and nuclear 
polymorphism, 
the absence of estrogen and progesterone receptors, 
the presence of lymph node metastasis, 
peritumoral vascular invasion. Other parameters such 
as the proliferating index (Ki 67, S-phase), the ploidy, 
and the presence of P53 or ERBB2 alteration may also 
be useful for prognostic evaluation or as predictive 
factors for therapeutic response. 
Genetics 
Note 
Familial breast cancers are thought to represent about 5 
to 10% of all breast cancers. 
 
 











Many of the chromosomal aberrations observed in 
breast carcinomas are not specific of this type of 
tumour; karyotypes of breast tumours frequently show 
multiclonality, suggesting the existence of a high 
degree of intratumoural heterogeneity. 
Alterations of chromosome arms 1q, 3p, 6q, 8p are 
often present; i(1q) and  der t(1;16) are frequent as sole 
anomalies; +7, +8 and +20 are also frequent; 
cytogenetic signs of DNA amplification, such as 
homogeneously staining regions (HSR), are commonly 
observed in breast carcinomas and seem preferentially 
associated to 8p. 
Molecular cytogenetics 
LOH studies: loss of heterozygosity (LOH) has been 
associated with physical deletion of large genomic 
segments containing tumour suppressor genes; 
common regions of LOH in breast cancer are located 
on several chromosomes: 1p, 1q, 3p, 6q, 8p, 11q, 13, 
16q, 17p, 17q; almost all breast tumours show LOH in 
one or several regions; some regions are lost in more 
than 50% of tumors: 8p, 16q, 17p; precancerous lesions 
also show LOH. 
CGH: Comparative genomic hybridization (CGH) is a 
molecular cytogenetics method designed to detect and 
map chromosomal regions showing abnormal copy 
numbers in tumors; theoretically, it is possible to detect 
equally copy number gains (DNA amplification or 
polyploidies) or losses using this approach; it appears, 
however, that CGH has a greater sensitivity for gains 
than for losses; this could be related to the fact tha
gains are generally of higher magnitude than losses and 
that losses can be obscured by intratumoral 
heterogeneity. 
Overall CGH data show that breast tumor genomes 
undergo severe rearrangements; on average, breast 
tumors show 5-7 copy number changes/tumor; less than 
10% of the tumors analyzed by CGH show neither 
gains nor losses; almost every chromosome presents at 
least one site with aberrant copy numbers, however, 
gains or losses are not evenly distributed throughot the 
genome. 
Hot spots for gains are routinely observed at 1q (50-
55% of the tumors), 8q (60%), 17q (25-30%), 20q (20-
25%); gains generally involve subregions of each 
chromosomal arm and most prevalent regions are 1q31-
q32, 8q12 and 8q24 (with MYC and other genes), 
17q12 (ERBB2) and 17q23-q24, and 20q13; other 
regions of recurrent gains are 11q13 (20%, with 
CCND1), 8p12 (10-15%, and FGFR1), 16p (10-15%); 
recurrent losses are observed at 1p, 6q, 8p, 11q23-qter, 
13q, 16q, 17p and 22q. 
CGH has revealed that copy number gains are common  
 
in breast tumors and involve 26 (!) chromosomal arms;  
these data somewhat contradict karyotypical analysis 
and LOH studies which indicate that losses are more 
frequent that gains; furthermore, it appears from CGH 
data that the number of events (gains and losses) 
increases in advanced cancer. 











H, K, and NRAS genes are a subfamily of the huge 
RAS/RHO/RAB superfamily and encode ubiquitous 
cytoplasmic GTP binding p21 proteins involved in 
signal transduction. 
Somatic mutations 
RAS genes are mutated at codons 12, 13 and 61in 
different types of cancers; the frequency of mutations 
in breast cancer is rather low (<10%) compared to 




DNA / RNA 
11 exons 
Protein 
The tumor suppressor gene P53 encodes an ubiquitous 
nuclear protein involved in the control of genome 
integrity by preventing cells from dividing before DNA 
damage is repaired; it has 5 conserved regions 
containing a transactivation domain, a DNA-binding 
domain, a tetramerization domain. 
Somatic mutations 
20-25% of breast cancers show P53 mutations and 
these correspond to aggressive breast tumors (loss of 
estrogen receptor expression). 
90% of P53 mutations are found within exons 5 
through 9, portions correspondig to codons 165-185 
(exon 5) and 235-252 (exon 7) concentrating 50% of 
the mutations (mutational hot spots); most frequently 
involved are codons 175, 248 and 273; mutations 
affecting residues 165-185 and 235-252 bear worse 
prognostic significance than others; these amino acid
residues are located in the L2 and L3 domains of the  
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p53 protein; both these domains bind a Zinc atom and 
convey contact to DNA; it may thus be of greater 
phenotypic significance. 
The majority of P53 mutations (80%) in breast cancer 
are missense, while nonsense mutations, deletions, 
insertions or, splice site mutations, which result in he 
truncation of the protein, make the rest (20%). 
Prolonged half-life of the protein can also be detected 






The ERBB2 (also called HER2 or NEU) gene encodes 
an integral type I protein of 185 kDa with a cysteine-
rich extracellular region, a transmembrane domain and 
an intracellular region endowed with a tyrosine kinase 
activity. 
Somatic mutations 
HER2 somatic mutations are reported in lung cancer, 
glioblastoma and ovarian tumor. No somatic mutations 
in human breast carcinoma are described. 
Amplification : the ERBB2 gene is amplified and 
overexpressed in 20-25% of breast tumors; tumors 
showing ERBB2 amplification have predominantly lost 
estrogen receptor expression (ER-) and are of ductal 
invasive type; interestingly, 70% of intraductal comedo 
carcinomas show ERBB2 expression, suggesting a role 
of this gene in the etiology of this breast tumor subtype; 
Although ERBB2 amplification and overexpression are 
related to a worsened course of the disease, they do not 
represent independent prognostic indicators; 
However, the p185-ERBB2 protein being a 
transmembrane receptor with low levels of expression 
in normal tissues has turned out to be a very interes ing 
target for therapeutical approaches; several protocols 
using engineered anti-ERBB2 antibodies have shown a 





The CCND1 gene codes for a cell cycle protein 
specifically acting in the G1 phase; upon interaction 
with cyclin dependent kinases (CDK4 or CDK6) cyclin 
D1 phosphorylates the p105-RB protein and thereby 
promotes progression in late G1 thus favoring entry 
into S phase; ectopic overexpression of CCND1 has 
been shown to result in shortened G1 phase and 
increased genetic instability, possibly due to a bypass 
of cell cycle checkpoints. 
Somatic mutations 
Amplification: the CCND1 gene is amplified in 
approximately 15% breast cancers; CCND1 
amplification is strongly correlated to expression of ER 
and is prevalent in invasive lobular carcinomas; 
univariate analysis and Cox model studies show that
CCND1 amplification is an independent prognostic 






The FGFR1 gene encodes an integral type I protein of 
145 kDa with an extracellular region made of three 
immunoglobulin-like domains, a transmembrane 
domain and an intracellular region endowed with a 
tyrosine kinase activity; alternative splicing create a 
large number of isoforms; it is a receptor for different 
members of the fibroblast growth factor family (FGF), 
which has about 20 members known to date. 
Somatic mutations 
Amplification: the 8p11-12 region is amplified in about 
10% of breast carcinomas; the FGFR1 gene is 
overexpressed as a consequence of the amplification, 
and is a good candidate for being the driver gene of the 
8p11-12 amplicon; FGFR1 is frequently amplified 
concomitantly with CCND1 (40% of FGFR1 amplified 
tumors also show CCND1 amplification); this 
coamplification of FGFR1 and CCND1 chromosomal 
regions results in the formation of a hybrid 
chromosomal structure in which amplified FGFR1 and 





Large gene of 22 coding exons spaning more than 70 
kb of genomic DNA; exon 11 corresponds to almost 
50% of the total coding sequence (5592 nucleotides); 
the BRCA1 mRNA has a size of 7.8 kb, and a complex 
pattern of alternative splicing has been reported; it is
expressed in numerous tissues (breast, ovary, testis, 
spleen, thymus ). 
Protein 
The corresponding protein has 1863 amino acids, and 
190-220 kDa; BRCA1 is not a member of any known 
gene family; there is only two stretches of evolutinary 
conserved sequences between humans and mice: at the 
N-terminus (the RING finger motif), and at the C-
terminus (the BRCT domain); the function of BRCA1 
is still unknown but it seems to act as a tumor 
suppressor gene with transcriptional activity; it is 
involved in cell proliferation processes of mammary 
epithelial cells in response to hormonal stimulation, in 
apoptosis, control of recombination and genome 
integrity after binding to proteins involved in these 
activities. 










More than 300 sequence variations at the germline 
level have been reported; a list is available on the BIC 
website: 
the germline mutations are dispersed throughout the 
coding sequence; although a majority of these 
variations are unique, recurrent mutations such as 
185delAG and 5382insC are observed; they were 
initially described in the Ashkenazy Jewish population; 
more than 80% of the sequence variants lead to a 
truncated protein; in contrast, the majority of missense 
mutations are of unknown clinical significance, 
excepted those in the RING finger region; in the 
BRCA1 families, an excess of breast, ovarian, and 
prostate cancers are seen; all  mutations combined, 
penetrance at age 70 years works out at 56% to 87% in 
the case of breast cancer, and 16% to 63% in that of 
ovarian cancer BRCA1-associated breast cancers have 
specific morphological features; they are more 
frequently of histoprognostic grade 3, highly 
proliferating and poorly differentiated tumors with a 
very pleomorphotic nuclear pattern; high frequencies of 
P53 alterations and negativity of steroid receptors are 
found in these tumors; a high rate of medullary breast 
carcinomas is observed among BRCA1-associated 
breast cancers; evidence for possible genotype-
phenotype correlations have been provided concerning 
the tumor spectrum (breast/ ovarian cancer incidence 
rate), the penetrance, and the proliferation rate of 
tumors. 
Somatic mutations 
In contrast, somatic mutations of BRCA1 coding 




DNA / RNA 
Like BRCA1 it is a large gene spanning more than 70 
kb of genomic DNA; the coding sequence comprises 26 
exons (10254 nucleotides) with three large ones (exons 
10, 11, 27); the mRNA is of 11-12 Kb long; like 
BRCA1, it is expressed in various tissues. 
Protein 
The coresponding protein has 3418 amino acid residu 
(384 kDa), and is poorly conserved, exepted for the 
BRC repeats region in exon 11 (8 copies of 20-30 aa); 
like BRCA1, its function remains unknown; however, 
it acts as a tumor suppressor gene; transcriptional 
activation properties have been reported as well as 
involvement in the DNA repair system. 
Germinal mutations 
More than 100 unique germ-line mutations are reported 
and are dispersed throughout the coding sequence (cf 
the BIC website, address above); recurrent mutations 
are seen: 6174delT (of Ashkenazy Jewish origin), 
999del5 (Icelandic), and 6503delTT (in France and in 
the UK); the majority lead to a truncated protein and 
are considered as disease-associated mutations, except 
for a polymorphic stop codon in exon 27; missense 
mutations are of uncertain clinical significance. 
BRCA2 germline mutations are associated with a high 
risk of male and female breast cancer; initially, the 
breast cancer risk was considered as equivalent to tha  
of BRCA1, but in a recent work based only on the 
Icelandic recurrent BRCA2 999del5 mutation, the 
estimated risk of breast cancer at age 70 years is 
considered of only 37%; the ovarian cancer risk is 
lower than that of BRCA1; in addition, an excess of 
prostate and pancreas cancers is also seen at the 
morphological level, BRCA2 breast cancers seem to be 
different from both BRCA1-associated breast cancers 
and sporadic cases, with a poor differentiation but no 
high proliferation rate; evidence for possible genotype-
phenotype correlation has been provided concerning 
the tumor spectrum (breast/ovarian cancer incidence 
rate). 
Somatic mutations 
Somatic mutations of BRCA2 coding sequence are rare 
in breast/ovarian cancers. 
BRCA3 
Location 
An important breakthrough in the understanding of 
breast carcinogenesis came with the identification of 
the two major genes BRCA1 and BRCA2, 
correponding to 52% and 32% of hereditary breast 
cancer families, respectively; however, the germline 
mutations of these genes do not account for all famili l 
cases; additional genes may be involved. 
One such gene might be located on chromosome arm 
8p; a positive linkage has first been found in a smll set 
of French families, and then a lod score of almost 3 was 
obtained in one German family; in addition, the 
chromosome 8p12-22 region seems to be frequently 
involved in breast carcinogenesis as well as in different 
types od tumors (lung, prostate, ovarian); while th
8p12-22 region remain a strong candidate locus, whole-
genome linkage studies are in progress to identify the 




DNA / RNA 
9 exons 
Protein 
The PTEN protein (also called MMAC1) is an 
evolutionary conserved dual-specificity phosphatase 
sharing extensive similarity with the cytoskeletal 
protein tensin; PTEN appears to be a tumor suppressor 
since biallelic inactivations are observed in several 
types of tumors; inactivating germline mutations are 
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responsible for a cancer prone syndrome, the Cowden 
disease (see below); also, PTEN -/- ES cells are highly 
tumorigenic in syngeneic mice whereas PTEN +/- are 
not. 
Germinal mutations 
Heterozygous germline mutations are responsible for 
the Cowden disease, a cancer prone syndrome with 
high susceptibility to breast carcinoma, and, to a lesser 
degree, to thyroid carcinoma; most of the mutations are 
inactivating mutations, either by leading to protein 
truncation, or by introducing alterations in the 
phosphatase catalytic domain; germline mutations are 
also seen in the Bannayan-Riley-Ruvalcaba syndrome. 
Somatic mutations 
In spite of the initial description of PTEN homozygous 
deletion in two breast tumor xenografts and biallelic 
inactivation of PTEN in two breast carcinoma cell 
lines, very few PTEN mutations have been observed in 
sporadic breast carcinoma (1 described mutation in 




DNA / RNA 
The ATM gene covers 150 kb of DNA and is spread 
over 64 exons. It codes for a 13.000 bp transcript, 
translated into a 3500 aa protein. 
Protein 
Nuclear protein showing homology at its carboxy 
terminus with PI-3 kinase; belongs to a family of DNA 
damage signaling proteins characterized in either yeast 
or Drosophila; ATM interacts with the ABL protein 
and is known to transmit a signal to the P53 protein. 
ATM activity seems restricted to double strand DNA 
breaks induced by ionising radiations or radio-
mimetics; it is noteworthy that the phenotype of Atm 
KO mice is very similar to that of ATM patients, but 
that heterozygous Atm +/- mutant mice do not show an 
increased incidence of cancer. 
Germinal mutations 
The ATM gene is the genetic determinant to ataxia 
telangiectasia, a rare recessive disorder, which among 
other clinical signs, is characterized by an extreme 
sensitivity to ionising radiations; it has been 
hypothesized that ATM could play a role in cancer 
predisposition because AT patients show a 100 fold 
increased risk of cancer, particularly  
hematological malignancies; furthermore, 
epidemiological studies have suggested that AT 
heterozygotes were also at increased risk of developing 
cancer, specially breast cancer in women; this, added to 
the fact that the ATM gene maps to 11q23, a region 
frequently affected by losses of heterozygosity, 
suggested that heterozygous mutations in the ATM 
gene may favor breast cancer development; ATM 
heterozygotes have been estimated to represent 1% of 
the total population. 
Most mutations reported in ATM kindreds result in the 
truncation of the protein. 
Mismatch repair genes 
Note 
MSH2 (2p21), MLH1 (3p21), PMS1 (2q31-33), PMS2 
/GTBP/MSH6 (7p22), MSH3 (5q). 
Protein 
The proteins encoded by the mismatch repair genes are 
analogues of the bacteria Mut HLS system which is 
involved in the reparation of DNA replication errors; 
their defect leads to genomic instability, the most 
visible consequence of which is the presence of 
additional alleles at microsatellite markers; the latter 
are prone to replication errors; their alteration is a 
hallmark of genomic instability, also called RER 
(replication error) or MSI (microsatellite instability) 
phenotype. 
Somatic mutations 
Frequencies of genomic instability varies from 0 to 
40% in breast cancer, depending on studies; however, 
mutations of mismatch repair genes are uncommon in 
breast cancer; thus, the high frequencies observed may 






Mutations and loss of expression of the E-cadherin 
gene, located on chromosome arm 16q, is very 
frequentlly observed in breast lobular carcinomas. 
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